文献速递主动脉疾病

医师改良支架移植物修复复杂腹主动脉瘤及胸腹主动脉瘤的五年结局

Five-year outcomes of physician-modified endografts for repair of complex abdominal and thoracoabdominal aortic aneurysms.
PubMed 文献 · J Vasc Surg · 2022-11-08

该研究回顾2007至2019年156例接受医师改良支架移植物行开窗分支血管腔内修复术的复杂腹主动脉瘤或胸腹主动脉瘤患者,30天和/或院内死亡率为5.7%,复杂腹主动脉瘤组显著低于胸腹主动脉瘤组(2% vs 10%,P=.04),5年患者生存率为41%,瘤囊回缩≥5 mm与生存改善相关(HR 0.54,95%CI 0.37-0.80)。

要点

  • 医师改良支架行开窗分支血管腔内修复术的30天和/或院内死亡率为5.7%,复杂腹主动脉瘤组2% vs 胸腹主动脉瘤组10%(P=.04)。
  • 5年患者生存率为41%,复杂腹主动脉瘤组无主动脉相关死亡、靶动脉不稳定、内漏及再干预均优于胸腹主动脉瘤组。
  • 瘤囊回缩≥5 mm见于67例(43%),与生存改善相关(HR 0.54,95%CI 0.37-0.80)。

核心结论

  • 使用医师改良支架行开窗分支血管腔内修复术可获得可接受的长期结局。
  • 总体患者生存率低,归因于显著的基础合并症。
  • 复杂腹主动脉瘤患者较胸腹主动脉瘤患者有更高的无主动脉相关死亡、靶动脉不稳定、靶动脉内漏、靶动脉再干预率,以及瘤囊增大≥5 mm无事件率的趋势。
  • 瘤囊回缩与患者生存改善相关。

研究设计与样本

  • 回顾性分析2007至2019年接受开窗分支血管腔内修复术使用医师改良支架治疗的复杂腹主动脉瘤和胸腹主动脉瘤患者的临床数据与结局。
  • 复杂腹主动脉瘤定义为短颈肾下腹主动脉瘤、近肾腹主动脉瘤和肾旁腹主动脉瘤。
  • 所有患者均由对市售器械有丰富经验的专门团队治疗。
  • 共纳入156例患者(男性121例;平均年龄75±8岁),占645例接受开窗分支血管腔内修复术患者的24%。
  • 包括89例复杂腹主动脉瘤、33例IV型胸腹主动脉瘤和34例I至III型胸腹主动脉瘤,共纳入452条肾-肠系膜靶动脉(每例患者3.1±1.0条血管)。

主要发现

  • 胸腹主动脉瘤患者较复杂腹主动脉瘤患者动脉瘤显著更大(73±11 vs 68±14 mm,P<.05),纳入靶动脉更多(3.4±0.9 vs 2.8±1.0),既往主动脉修复史更常见(54% vs 27%)。
  • 复杂腹主动脉瘤患者技术成功率高于胸腹主动脉瘤患者(99% vs 91%,P=.04)。
  • 30天和/或院内死亡率为5.7%,复杂腹主动脉瘤组显著低于胸腹主动脉瘤组(2% vs 10%,P=.04),9例早期死亡中3例(33%)为急诊治疗患者。
  • 平均随访49±38个月,主动脉相关死亡12例(7.6%),包括9例早期死亡(5.7%)源于围手术期并发症和3例晚期死亡(1.9%)源于破裂。
  • 5年患者生存率为41%;复杂腹主动脉瘤组较胸腹主动脉瘤组有更高的5年无主动脉相关死亡率(P=.016)、无靶动脉不稳定率(P=.05)、无靶动脉内漏率(P=.01)、无靶动脉再干预率(P=.05),以及更高的无瘤囊增大≥5 mm率但未达统计学显著(P=.11)。

关键数值与推荐

  • 靶动脉一期和二期通畅率分别为91%±2%和99%±1%。
  • 瘤囊回缩≥5 mm发生于67例患者(43%),与生存改善相关(HR 0.54,95%CI 0.37-0.80)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is paucity of data on the durability of physician modified endografts (PMEGs) for complex abdominal (CAAAs) and thoracoabdominal aortic aneurysms (TAAAs) despite widespread use. The aim of this study was to evaluate and compare the early and long-term outcomes of fenestrated-branched endovascular aortic repair (FB-EVAR) for CAAAs and TAAAs using PMEGs. METHODS: We reviewed clinical data and outcomes of patients treated by FB-EVAR using PMEGs for CAAAs (defined as short-neck infrarenal, juxtarenal, and pararenal AAAs) and TAAAs between 2007 and 2019. All patients were treated by a dedicated team with extensive manufactured device experience. Endpoints included 30-day mortality and major adverse events, patient survival and freedom from aortic-related mortality (ARM), freedom from secondary intervention, target artery (TA) patency, and freedom from TA endoleak and TA instability. RESULTS: Of 645 patients undergoing FB-EVAR, 156 patients (24%) treated with PMEG (121 males; mean age, 75 ± 8 years) were included. There were 89 CAAAs, 33 extent IV TAAAs and 34 extent I to III TAAAs. A total of 452 renal-mesenteric targets (3.1 ± 1.0 vessels/patient) were incorporated. Patients with TAAAs had significantly (P < .05) larger aneurysms (73 ± 11 vs 68 ± 14 mm), more TAs incorporated (3.4 ± 0.9 vs 2.8 ± 1.0), and more often had previous aortic repair (54% vs 27%). Technical success was higher in patients treated for CAAAs (99% vs 91%; P = .04). Thirty-day and/or in-hospital mortality was 5.7% and was significantly lower for CAAAs compared with TAAAs (2% vs 10%; P = .04), with three of nine early mortalities (33%) among patients treated emergently. After a mean follow-up of 49 ± 38 months, there were 12 aortic-related deaths (7.6%), including nine early deaths (5.7%) from perioperative complications and three late deaths (1.9%) from rupture. At 5 years, patient survival was 41%. Patients treated for CAAAs had higher 5-year freedom from ARM (P = .016), TA instability (P = .05), TA endoleak (P = .01), and TA secondary interventions (P = .05) with a higher, but non-significant, freedom from sac enlargement ≥5 mm (P = .11). Primary and secondary TA patency was 91% ± 2% and 99% ± 1%, respectively. Sac regression ≥5 mm occurred in 67 patients (43%) and was associated with increased survival (hazard ratio, 0.54; 95% confidence interval, 0.37-0.80) compared with those without sac regression. CONCLUSIONS: FB-EVAR using PMEGs was performed with acceptable long-term outcomes. Overall patient survival was low due to significant underlying comorbidities. Patients treated for CAAAs had higher freedom from ARM, TA instability, TA endoleak, TA secondary interventions, and a trend towards higher freedom from sac enlargement compared with patients treated for TAAAs. Sac regression was associated with improved patient survival.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Chait J, Tenorio ER, Hofer JM, et al. Five-year outcomes of physician-modified endografts for repair of complex abdominal and thoracoabdominal aortic aneurysms. J Vasc Surg. 2022. PMID: 36356675. doi:10.1016/j.jvs.2022.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。